Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002261202 | SCV002541790 | uncertain significance | not provided | 2021-08-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002360888 | SCV002662117 | uncertain significance | Cardiovascular phenotype | 2021-09-21 | criteria provided, single submitter | clinical testing | The p.Q2353K variant (also known as c.7057C>A), located in coding exon 26 of the APOB gene, results from a C to A substitution at nucleotide position 7057. The glutamine at codon 2353 is replaced by lysine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002487590 | SCV002793262 | uncertain significance | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2021-11-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002487590 | SCV003198111 | likely benign | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2024-07-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002261202 | SCV003853133 | uncertain significance | not provided | 2022-09-06 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |